In the field of ovarian cancer, the SOLO1 phase III study (NCT01844986) reveals that maintenance therapy with olaparib results in a shorter PFS among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olaparib than with placebo [32]. Here, BRCA1 is linked to ovarian cancer.